Cybin Inc. Common StockHELP

$4.67+0.09 (+1.97%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$113M

Micro-cap

-21%

2025 — today

10-Year Price

-21%

2025 — today

52-Week Range

$3.81$8.71

Current $4.67· 18%

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Valuation in context

P/E ratio

-0.7

N/A

Not meaningful — company is unprofitable

P/B ratio

0.4

Historically cheap

Historically cheap relative to the last 10 years

FCF Yield

-110.6%

Historically low

Historically low relative to the last 10 years

Free · No credit card needed

Get alerted when HELP is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.